9.JPG)
The Global AI-Based Digital Pathology Solutions Market is predicted to grow at an 8.59% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The increasing focus on cost management and efficiency improvement in hospitals, the increasing demand for technologically advanced solutions, and the increasing frequency of misdiagnoses drive market growth.
- Government-funded research programs that encourage the development of innovative digital tools for pathology are expected to fuel industry expansion.
- North America dominated the market and accounted for a revenue share of global revenue in 2023.
- Interoperability worries and high initial and ongoing operating expenses will likely slow the market's growth.
Artificial Intelligence (AI) has been proven to be a faster and more effective approach to identifying and assessing pathological characteristics in samples than previous techniques. The drug discovery process is made more efficient and effective by implementing AI, and the diagnosis process can be accelerated and strengthened. In addition, AI aids pathologists in making accurate diagnoses by using data to verify their findings. It can alert them when their conclusions are contrary to what is expected based on the algorithms. As a result, AI-based pathology solutions may become increasingly popular.
By combining Artificial Intelligence (AI) with digital pathology, pathologists can now perform image analytics on a more significant number of slides in a shorter period by combining AI and digital pathology as a validation tool. Pathologists can improve outcomes by focusing on specific regions and improving efficiency accordingly. Digital pathology is enhancing patient engagement with the use of artificial intelligence, with devices and apps providing access to electronic health records, radiology images, etc.
It is becoming increasingly common to use artificial intelligence in healthcare, particularly in pathological diagnosis, to improve patient care. For example, a clinical decision support system is an AI-based tool designed to streamline workflow processes and enhance hospital patient care. The Roche Group announced in October 2021 that it had agreed with PathAI, an artificial intelligence-based pathology technology leader. The agreement outlines the development and distribution of an embedded image analysis workflow to be used by pathologists under this development and distribution contract. An AI-based medical device will be developed as a result of this partnership, which will include a scanner, an assay, a management system, and an algorithm.
Research collaborations and the growth of digital documentation are driving an increase in adoption across all scientific disciplines. The increasing penetration of healthcare IT solutions has boosted the demand for digital pathology solutions. In recent years, many organizations have adopted resolutions to decrease costs, reduce resource bottlenecks, automate processes, and effectively share content. Advancements in technologies, such as microarrays and predictive models, including hybrid models and API algorithms, will also fuel the demand for digital image analysis.
Several factors contribute to the restraints on the market, including the requirement for high capital, which hinders the company's global reach expansion, and a lack of tools necessary to conduct a computational analysis. Also, many factors could limit the market's growth, including a shortage of experienced professionals and a lack of awareness of modern spatial-based technology.
Competitive Landscape
Some major key players in the AI-Based Digital Pathology market
- PathAI,
- Paige.AI,
- Akoya Biosciences,
- Aiforia,
- aetherAI,
- CellCarta,
- Deep Bio Inc.,
- DoMore Diagnostics,
- PROSCIA,
- Pramana, Inc.,
- Visiopharm A/S,
- Roche Tissue Diagnostics,
- Indica Labs,
- Ibex Medical Analytics,
- LDPath,
- OracleBio Limited,
- Verily,
- Mindpeak GmbH,
- Proscia Inc.,
- SamanTree Medical SA,
- Tempus AI,
- Techcyte, Inc.,
- Tribun Health
Market Segmentation:
The AI-Based Digital Pathology market is segmented by type of neural network, assay type, type of target disease indication, application, and end-user. All of these segments are subdivided into respective segments. The type of neural network segment has artificial, convolutional, fully convolutional, recurrent neural, and others, respectively. The type of assay category comprises ER assay, HER2 assay, Ki67 assay, PD-L1 assay, PR assay, and other assays. The target disease indication segment includes breast cancer, colorectal cancer, cervical cancer, gastrointestinal cancer, lung cancer, prostate cancer, and other indications. Also, the application segment includes diagnosis, research, and other applications. The last segment is the end-user segment which contains academic institutions, hospitals/healthcare institutions, laboratories/diagnostic institutions, research institutes and other end-users.
In 2021, North America dominated the market with a significant share. A major factor driving North America's share of the AI-based digital pathology market is improved healthcare infrastructure, increased per capita income, and the availability of state-of-the-art research laboratories and institutes. The FDA categorizes DP as a Class II device for primary diagnosis. Digital pathology is poised to become an increasingly vital tool to enhance disease diagnosis and improve the quality of pathology services. The market is expected to benefit from this development across the nation.
Recent Developments:
- In January 2024, Roche announced that it had entered into a final merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately held US company in Berkeley, California. A variety of preclinical programs and clinically stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes are part of Carmot's research and development portfolio.
- In November 2023, Leica Biosystems further strengthened its partnership with hospitals and laboratories worldwide later to make use of the innovative digital pathology workflows. Building on their prior partnership, Leica Biosystems has selected Paige to supply their Aperio GT 450 digital pathology slide scanners with view and manage digital pathology images software and a range of embedded AI technologies.
AI-Based Digital Pathology Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.59% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type of Neural Network, Type Of Assay, Type Of Target Disease Indication, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
PathAI, Paige.AI, Akoya Biosciences, Aiforia, aetherAI, CellCarta, Deep Bio Inc., DoMore Diagnostics, PROSCIA, Pramana, Inc., Visiopharm A/S, Roche Tissue Diagnostics, Indica Labs, Ibex Medical Analytics, LDPath, OracleBio Limited, Verily, Mindpeak GmbH, Proscia Inc., SamanTree Medical SA, Tempus AI, Techcyte, Inc., Tribun Health. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
